Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137221 | Leukemia Research | 2013 | 7 Pages |
Abstract
In vivo effects of the DNA hypomethylating agent 5-aza-2′-deoxycytidine (DAC) upon the epigenome of acute myeloid leukemia (AML) patients are scarcely studied in primary blasts. Here, we sequentially assessed DNA methylation and transcriptome changes in myeloblasts of DAC-treated AML patients. DNA methylation changes were detected in all patients already after the first series of infusion (median: 6 days). LINE1 analysis indicated global DNA methylation decrease in 7/8 patients. Gene-specific hypomethylating effects were not directly linked to mRNA expression changes. In conclusion, complex DAC-induced DNA methylation changes occur very early and imply mechanisms distinct from non-hypomethylating cytosine analogs.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rainer Claus, Dietmar Pfeifer, Maika Almstedt, Manuela Zucknick, Björn Hackanson, Christoph Plass, Michael Lübbert,